AI assistant
Nuvectis Pharma, Inc. — Director's Dealing 2023
Jun 26, 2023
33912_dirs_2023-06-26_9f2da2ee-f7b9-4d18-8ba8-21cda11624ae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2023-06-23
Reporting Person: Mosseri Marlio Charles (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-23 | Common Stock | P | 73175 | $17.43 | Acquired | 2511265 | Direct |
Footnotes
F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $16.9149 to $17.7559. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.